HHS peptide compounding policy splits pharmacists and pharmacologists

WASHINGTON. The HHS peptide compounding policy dated October 28 lets licensed pharmacies make six unapproved peptides while federal officials hold off on enforcement, and it has split pharmacists from pharmacologists. The Alliance for Pharmacy Compounding called it a safer path than the gray market, according to Everyday Health. Two pharmacology professors told the outlet the products have never passed the testing the FDA requires for approval. The policy itself does not claim the six are safe or effective, the report said.

What the HHS policy covers

The HHS peptide compounding policy is titled HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, according to the Everyday Health source list. The outlet, whose report Yahoo News carried on October 29, said HHS adopted it quietly and that it applies for a limited time. It covers BPC 157, epitalon, KPV, MOTS c, Semax and TB 500, which pharmacies may now prepare from bulk ingredients. Everyday Health linked the six to wellness influencers and to HHS Secretary Robert F. Kennedy Jr., who has championed them. Peptide Zone set out the first details of the text in an earlier report. This story follows the reaction and the open questions about how far the policy reaches.

The six names trace back to a July meeting. The FDA's Pharmacy Compounding Advisory Committee met on July 23 and 24, 2026, at the agency's White Oak campus in Silver Spring, Maryland. It weighed seven peptide bulk substances for the 503A Bulks List, the list of ingredients that traditional pharmacies may use. The seventh, emideltide, also called delta sleeping inducing peptide, does not appear among the six in the policy as reported. Advisory committees give the FDA advice that is not binding, the agency's meeting page says. The table above pairs each peptide with the uses FDA reviewers evaluated. Everyday Health said those uses remain unproven by rigorous scientific standards.

Enforcement discretion is not approval

The HHS peptide compounding policy did not approve the six peptides or add them to any approved list. Instead HHS said it will use enforcement discretion, which Everyday Health described as the agency choosing not to act when pharmacies make and sell the products. The outlet stressed that this step does not make the compounding legal. Enforcement discretion means HHS has said it will not pursue pharmacies that make the six peptides, but the products remain unapproved drugs. The FDA says compounded drugs in general are not FDA approved and that it does not check their safety, effectiveness or quality before patients receive them. The policy rests on no new research into the peptides, the report said.

Enforcement discretion means HHS has said it will not pursue pharmacies that make the six peptides, but the products remain unapproved drugs.

Jamie Alan, an associate professor at Michigan State University who studies drugs and toxic effects, drew the same line. HHS "is just saying they won't take action if compounders make this, which is not the same as saying this is safe and it works," she told Everyday Health. Arindam Bhattacharjee, a Buffalo based pharmacology professor in the SUNY system, said the six "have not gone under the typical rigorous testing of clinical trials." He called bypassing the FDA "dangerous." He also pointed to two guardrails in the text. Ingredients must come only from FDA registered factories, he said, and each finished product must pass chemical identity and purity testing. The report does not describe how HHS will check that pharmacies meet those terms.

Pharmacists cite gray market peptides

The Alliance for Pharmacy Compounding, which represents compounding pharmacies, welcomed the move in a statement on Thursday, October 29. "Right now, far too many patients are obtaining peptides from illicit suppliers with little assurance about what's actually in the vial," the group said. It argued that this risk will not go away simply because compounding is banned. Letting licensed pharmacies prepare the products "offers a more accountable alternative," the statement said. Everyday Health framed the group's case around the many Americans who already obtain gray market peptides in pursuit of better health and a longer life. The statement, as quoted, gave no figures on how many people use these products or on harms linked to them. Peptide Zone has reported separately on seized vials in Iceland that did not match their labels.

Pharmacologists reject the trade. "This is dangerous," Alan told Everyday Health. "People will be hurt, and people will probably die." She urged people to ask why large drug makers are not already selling the six if they are as safe and effective as claimed. She also advised caution toward any pharmacy that compounds them, licensed or not, because adequate safety data do not exist. The objection is not new. Before the policy appeared, researchers at the Center for Science in the Public Interest argued in a JAMA Viewpoint that opening compounding to these peptides could undercut the drug approval system. None of the six has completed the clinical trials that FDA approval requires, according to the report.

Prescriptions and outsourcing facilities

The HHS peptide compounding policy keeps one standard rule for traditional pharmacies. Products "must be compounded based on the receipt of a valid patient-specific prescription," the policy says, as quoted by Everyday Health. That matches the 503A compounding rules in the Federal Food, Drug, and Cosmetic Act. Under federal compounding law, outsourcing facilities registered under a separate Section 503B follow factory quality rules, face risk based FDA inspections and must report adverse events. They may also supply a hospital or clinic with office stock without naming a patient. Congress created that category in November 2013, the FDA says, after a 2012 outbreak tied to a Massachusetts pharmacy caused more than 750 infections and more than 60 deaths in 20 states.

Alan flagged that second route as a gap. She told the outlet that outsourcing facilities could supply the peptides to provider offices and medical spas, where patients would not need their own prescription. The report does not say whether the HHS text reaches outsourcing facilities, and the policy title names only Section 503A. Peptide Zone could not confirm that point from the policy document itself. The report also gives no end date for the temporary arrangement. In the sources reviewed for this story, the FDA has not announced a final decision on adding the six to the 503A Bulks List. Bhattacharjee added that peptides may interact with other medicines, so patients should tell their doctors about any use. Alan urged people to talk to a health care provider first.

Conclusion

The HHS peptide compounding policy changes federal enforcement, not the evidence. Six peptides the FDA has never approved can now be compounded by licensed pharmacies on a patient prescription while HHS holds back, according to Everyday Health. Pharmacists say that beats the gray market. Pharmacologists say it exposes patients to products with no proven benefit. Open questions include how long the policy lasts, how its quality terms will be checked and whether outsourcing facilities fall under it. This report is for news and research purposes and is not medical advice.